{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:40:03Z","timestamp":1781865603478,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.01.046","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T09:04:44Z","timestamp":1644570284000},"page":"1872-1878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older"],"prefix":"10.1016","volume":"40","author":[{"given":"Johannes","family":"Beeslaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-255X","authenticated-orcid":false,"given":"Joseph J.","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.01.046_b0005","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.046_b0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jpids\/piv065","article-title":"The health burden of invasive meningococcal disease: a systematic review","volume":"5","author":"Strifler","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2022.01.046_b0015","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.046_b0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2022.01.046_b0025","unstructured":"Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2016, https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report.pdf; [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2022.01.046_b0030","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases, https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases; 2019 [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2022.01.046_b0035","unstructured":"Uppsala Monitoring Centre. Glossary of pharmacovigilance terms, https:\/\/who-umc.org\/media\/1471\/setting-up-a-pv-centre-en.pdf; 2000 [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2022.01.046_b0040","unstructured":"Department of Health and Human Services, US Food and Drug Administration. Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products: Guidance for Industry, https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM625241.pdf; 2018 [February 2, 2022]."},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.046_b0045","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults","volume":"8","author":"Sheldon","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.046_b0050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.046_b0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.046_b0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.046_b0065","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.vaccine.2016.01.044","article-title":"A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults","volume":"34","author":"Ostergaard","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.046_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"24","key":"10.1016\/j.vaccine.2022.01.046_b0075","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.046_b0080","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.046_b0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.046_b0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.vaccine.2015.12.016","article-title":"Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers","volume":"34","author":"Reiner","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.046_b0095","unstructured":"Institute of Medicine. Adverse effects of vaccines: evidence and causality, https:\/\/www.nap.edu\/catalog\/13164\/adverse-effects-of-vaccines-evidence-and-causality, 2012 [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2022.01.046_b0100","first-page":"472","article-title":"Two-dose MenB-FHbp (Trumenba) for meningococcal disease prevention","volume":"70","author":"Venard","year":"2017","journal-title":"S D Med"},{"key":"10.1016\/j.vaccine.2022.01.046_b0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba\u00ae): a review in active immunization against invasive meningococcal group B disease in individuals aged 10\u201325 years","volume":"29","author":"Shirley","year":"2015","journal-title":"Biodrugs"},{"key":"10.1016\/j.vaccine.2022.01.046_b0110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-018-0869-7","article-title":"MenB-FHbp meningococcal group B vaccine (Trumenba\u00ae): a review in active immunization in individuals aged \u2265 10 years","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.046_b0115","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/INF.0000000000001742","article-title":"Adverse events following vaccination with bivalent rLP2086 (Trumenba\u00ae): an observational, longitudinal study during a college outbreak and a systematic review","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:20Z","timestamp":1759403420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22000925"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}